Last reviewed · How we verify
Viekira Pak ± ribavirin
Viekira Pak is a fixed-dose combination of three direct-acting antivirals (ombitasvir, paritaprevir, and ritonavir) that inhibit hepatitis C virus NS5A and NS3/4A proteases to block viral replication.
Viekira Pak is a fixed-dose combination of three direct-acting antivirals (ombitasvir, paritaprevir, and ritonavir) that inhibit hepatitis C virus NS5A and NS3/4A proteases to block viral replication. Used for Chronic hepatitis C virus (HCV) genotype 1 infection, with or without cirrhosis, HCV genotype 4 infection (in combination with ribavirin).
At a glance
| Generic name | Viekira Pak ± ribavirin |
|---|---|
| Also known as | AbbVie 3D regimen |
| Sponsor | Massachusetts General Hospital |
| Drug class | Direct-acting antiviral (DAA) combination |
| Target | HCV NS5A protein, HCV NS3/4A serine protease |
| Modality | Small molecule |
| Therapeutic area | Virology / Hepatology |
| Phase | FDA-approved |
Mechanism of action
Ombitasvir targets the NS5A protein essential for HCV RNA replication and virion assembly. Paritaprevir inhibits the NS3/4A serine protease required for viral polyprotein processing. Ritonavir acts as a pharmacokinetic booster to increase paritaprevir levels. Ribavirin, when added, is a nucleoside analog that increases mutation rates in the viral genome. Together, these agents prevent hepatitis C virus from replicating and spreading.
Approved indications
- Chronic hepatitis C virus (HCV) genotype 1 infection, with or without cirrhosis
- HCV genotype 4 infection (in combination with ribavirin)
Common side effects
- Fatigue
- Headache
- Nausea
- Pruritus
- Anemia (when ribavirin added)
- Elevated bilirubin
Key clinical trials
- Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P (PHASE3)
- Study of Oral Treatments for Hepatitis C (PHASE4)
- Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C (PHASE4)
- DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO) (PHASE2, PHASE3)
- A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults (PHASE3)
- A Study to Evaluate Chronic Hepatitis C Infection (PHASE3)
- A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C (PHASE3)
- A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Viekira Pak ± ribavirin CI brief — competitive landscape report
- Viekira Pak ± ribavirin updates RSS · CI watch RSS
- Massachusetts General Hospital portfolio CI